Trials / Completed
CompletedNCT00010413
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (planned)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
Detailed description
PROTOCOL OUTLINE: Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover. Patients are followed monthly for 6 months, every 2 months for 6 months, every 4 months for a year, and then annually thereafter.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cyclophosphamide | |
| DRUG | filgrastim |
Timeline
- Start date
- 1999-04-01
- Primary completion
- 2007-08-01
- First posted
- 2001-02-02
- Last updated
- 2008-10-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00010413. Inclusion in this directory is not an endorsement.